Diagnos Inc. (ADK:tsxv) is a leader in artificial intelligence and healthcare technical services including algorithm development, data analysis, and image processing ever since 2001. CARA, which has been developed by and is proprietary to Diagnos Inc., is an innovative software program that uses enhanced digital images to support and identify the early detection of vision loss and more specifically diabetic retinopathy. CARA is a teleophthalmology platform which includes advanced retinal imaging technology and clinical grading services by eye care professionals.

Highlights:

1. Diagnos Inc. offers a tailored solution to pharmaceutical companies, as well as to public and parapublic organizations (Governments).
2. Management has over 50 years of combined experience working on artificial intelligence in the tech, science and healthcare space.
3. The AI market for healthcare applications is expected to achieve rapid adoption globally, with a compound annual growth rate (CAGR) of 42% until 2021.
4. By 2020, chronic conditions such as cancer and diabetes are expected to be diagnosed in minutes using cognitive systems.
5. Their proprietary technology CARA, integrates with almost any type of camera allowing a seamless automation of detection of pathology in retinal photographs.